Skip to primary navigation
Skip to main content
Skip to primary navigation
Skip to main content
Toggle Search
Search
Choose which site to search.
Current site
All of UAMS
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller
Cancer Institute
UAMS Health
Jobs
Giving
Toggle Search
Toggle Primary Nav
About
From the Director
Our History
Leadership
Board of Advisors
Health Equity and Workforce Development
About Little Rock
Maps & Directions
Cancer Institute Magazine
News
College of Medicine
Patient Care
Clinical Trials
Research
Research Programs
Membership
Clinical Research
Funding Opportunities
Shared Resources
Training and Education
Get Involved
Donate
Fundraising Events
Volunteer Services & Auxiliary
The Envoys
Contact
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute
Gynecologic Cancer
Trials: Gynecologic Cancer
Disease Sites Included: Cervical, Ovarian, Uterus/Endometrial, Vaginal, Vulvar
You are here:
Find a Clinical Trial
Gynecologic Cancer
NCT03997370 – NRG-GY022 Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
December 6, 2024
NCT04095364 – NRG GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
July 24, 2024
NCT04930159 – The Social Interventions for Support during Treatment for Endometrial Cancer and Recurrence (SISTER) Study
July 24, 2024
NCT05256225 – NRG-GY026: a Phase ii/iii Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) in Her2 positive, Stage i-iv Endometrial Serous Carcinoma or Carcinosarcoma
June 20, 2024
NCT05440760 – Using Virtual Reality Technology to Improve Patient Experience and Quality of Care during Brachytherapy
July 24, 2024
NCT05548296 – A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
June 20, 2024
NCT05611931 – A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
September 18, 2024
NCT06072781 – A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
September 18, 2024
NCT06433219 – An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deficiency (HRD)-positive epithelial ovarian cancer that progressed on prior PARP inhibitor therapy
November 15, 2024
